Xenon Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA98420N1050

SecurityXENE / Xenon Pharmaceuticals Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership609,929 shares
Latest Disclosed Value $ 35,467,371
Standard Life Aberdeen plc reports 18.71% decrease in ownership of XENE / Xenon Pharmaceuticals Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 609,929 shares of Xenon Pharmaceuticals Inc. (US:XENE) valued at $35,467,371 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 750,291 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of -18.71% during the quarter. The current value of the position is $31,551,627 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 609,929 -140,362 -18.71 35,467 5.47 0.0311
2026-01-16 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 750,291 171,146 29.55 33,628 44.62 0.0521
2025-11-07 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 579,145 57,653 11.06 23,253 42.46 0.0368
2025-07-24 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 521,492 117,338 29.03 16,323 20.38 0.0278
2025-05-13 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 404,154 120,255 42.36 13,559 21.85 0.0264
2025-01-24 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 283,899 35,588 14.33 11,129 13.83 0.0209
2024-10-25 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 248,311 35,809 16.85 9,776 18.00 0.0179
2024-08-09 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 212,502 180,466 563.32 8,285 500.80 0.0159
2024-05-09 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 32,036 0 0.00 1,379 -6.51 0.0027
2024-01-31 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 32,036 32,036 1,476 0.0032
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.